Updates are available Correction dated 2024-03-11
Click to view Correction: https://doi.org/10.1038/s41591-024-02910-1
Updates are available Correction dated 2025-04-16
Click to view Correction: https://doi.org/10.1038/s41591-025-03709-4
-
Authors
Kilburn, Lindsay B. https://orcid.org/0000-0003-1478-3619
Khuong-Quang, Dong-Anh https://orcid.org/0000-0001-6305-7790
Hansford, Jordan R. https://orcid.org/0000-0001-7733-383X
Landi, Daniel
van der Lugt, Jasper https://orcid.org/0000-0002-8186-338X
Leary, Sarah E. S. https://orcid.org/0000-0003-0225-6184
Driever, Pablo Hernáiz https://orcid.org/0000-0003-3135-3872
Bailey, Simon https://orcid.org/0000-0003-4763-4329
Perreault, Sébastien
McCowage, Geoffrey
Waanders, Angela J.
Ziegler, David S. https://orcid.org/0000-0001-7451-7916
Witt, Olaf
Baxter, Patricia A.
Kang, Hyoung Jin https://orcid.org/0000-0003-1009-6002
Hassall, Timothy E.
Han, Jung Woo https://orcid.org/0000-0001-8936-1205
Hargrave, Darren https://orcid.org/0000-0001-8219-9807
Franson, Andrea T. https://orcid.org/0000-0002-5361-7683
Yalon Oren, Michal
Toledano, Helen
Larouche, Valérie https://orcid.org/0000-0003-4082-7267
Kline, Cassie https://orcid.org/0000-0001-7765-7690
Abdelbaki, Mohamed S.
Jabado, Nada https://orcid.org/0000-0003-2485-3692
Gottardo, Nicholas G. https://orcid.org/0000-0002-1082-6776
Gerber, Nicolas U. https://orcid.org/0000-0002-1783-631X
Whipple, Nicholas S.
Segal, Devorah https://orcid.org/0000-0002-9740-1286
Chi, Susan N.
Oren, Liat
Tan, Enrica E. K.
Mueller, Sabine https://orcid.org/0000-0002-8216-9357
Cornelio, Izzy
McLeod, Lisa
Zhao, Xin
Walter, Ashley
Da Costa, Daniel
Manley, Peter
Blackman, Samuel C.
Packer, Roger J.
Nysom, Karsten https://orcid.org/0000-0003-2935-0058
- License Information
-
More Information
Article History
Received: 15 September 2023
Accepted: 25 October 2023
First Online: 17 November 2023
Change Date: 11 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-024-02910-1
Change Date: 16 April 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-025-03709-4
Competing interests
: L.B.K. has received consulting fees from Blueprint Medicine as DSMB Chair and has contracted institutional research with Novartis, Regeneron Pharmaceuticals, Day One Biopharmaceuticals, Spring Works Therapeutics, Bristol Myers Squibb and SonALAsense. L.B.K. also owns stock in Onconova Therapeutics. J.R.H. has received honoraria for consultation from Bayer, Alexion Pharma and Boxer Capital. P.H.D. is on an advisory board with Alexion and is part of the Alexion ICI Sprinkle Study. S.P. is on advisory boards with Bayer, Alexion and Esai and has received research support from Novartis, Bayer and Roche. D.S.Z. has received consulting/advisory board fees from Bayer, AstraZeneca, Accendatech, Novartis, Day One Biopharmaceuticals, FivePhusion, Amgen, Alexion and Norgine and has received research support from Accendatech. O.W. is on advisory boards with Novartis, Janssen, Roche, Bristol Myers Squibb and AstraZeneca and has received research grants from Day One Biopharmaceuticals, Biomed Valley Discovery, Bristol Myers Squibb, Syndax and PreComb. H.J.K. is on advisory boards with Novartis, Jazz Pharmaceuticals, Takeda, Cartexell and GPCR. D.H. is on advisory boards with Alexion/AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Day One Biopharmaceuticals, Janssen, Novartis and Roche and has received research grants from Alexion/AstraZeneca and Roche. V.L. is on an advisory board with Alexion. C.K. is a study chair of an investigator-sponsored trial for which Day One Biopharmaceuticals provides drug and research support; she also has research relationships with other industry partners. D.S. is on an advisory board with Alexion. L.M., X.Z., A.W., D.D., P.M., I.C. and S.C.B. are employees of Day One Biopharmaceuticals and have received Day One Biopharmaceuticals stock and stock options. K.N. has received advisory board or consulting fees from Y-mAbs, EUSA Pharma, Bayer and Eli Lilly. All remaining authors declare no competing interests.
